Results 151 to 160 of about 56,264 (258)

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, Volume 183, Issue 9, Page 1727-1746, May 2026.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

Cancer Science, Volume 117, Issue 5, Page 1223-1234, May 2026.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa, Satoko Ugai, Atsushi Kondo, Kosuke Matsuda, Shu Kato, Genki Usui, Shiori Tanaka, Hwa‐Young Lee, Xinyuan Zhang, Hideo Miyagawa, Mai Chan Lau, Hiroshi Saeki, Yukihide Kanemitsu, Andrew T. Chan, Shuji Ogino, Minkyo Song, Juha P. Väyrynen, Tomotaka Ugai   +17 more
wiley   +1 more source

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

Therapeutics and Clinical Risk Management, 2016
Mary Lou Affronti,1–3 Sarah Woodring,1,2 Katherine B Peters,1,4 James E Herndon II,5 Frances McSherry,5 Patrick N Healy,5 Annick Desjardins,1,4 James J Vredenburgh,6 Henry S Friedman1,2 1The Preston Robert Tisch Brain Tumor Center at Duke ...
Affronti ML, Woodring S, Peters KB, Herndon II JE, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS   +8 more
doaj  

The Role of Gut Microbiota and Their Derived Metabolites in Chemotherapy-Induced Nausea and Vomiting in Ovarian Cancer. [PDF]

Cancer Med
Zu S, Yu X, Song J, Xiao Y, Yi H, Li H.
europepmc   +1 more source

Incidence and Risk Factors of Delayed Chemotherapy-Induced Nausea and Vomiting Among Adult Patients: A Cross-Sectional Study. [PDF]

Nurs Open
Zheng M, Zhang Q, Ni L, Zheng Z, Wang Y, Chen Y, Huang J, Gao J, Li Q, Zhang Y.   +9 more
europepmc   +1 more source

Risk prediction models for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. [PDF]

Front Oncol
Xie X, Li H, Li Y, Fu H, Wang Y, Cheng J.   +5 more
europepmc   +1 more source

Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program. [PDF]

Support Care Cancer
Caponero R, Enrico D, Giudice F, Ayoub JP, Lapointe N.   +4 more
europepmc   +1 more source

Development and pharmacokinetic evaluation of granisetron hydrochloride buccal tablets for optimized chemotherapy-induced nausea and vomiting (CINV) relief. [PDF]

Front Pharmacol
Thalluri C, Naik Bukke SP, Vasam M, Medhi J, Chettupalli AK, Mamilla Mugaiahgari BK, Narapureddy BR, Yata VK, Chander Thatipelli R.   +8 more
europepmc   +1 more source

Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy. [PDF]

BMC Cancer
Yamashita A, Hayashi T, Shimokawa M, Harimitsu Y, Nishijima Y, Uchiyama M, Ushio S, Shiraishi C, Miyoshi T, Koutake Y, Kawada K, Matsuo K, Egawa T.   +12 more
europepmc   +1 more source

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer [PDF]

, 2016
Basch, Bauters, Bodge, Chanthawong, Choi, Choo, Dupuis, Dupuis, Dupuis, Dupuis, Flank, Flank, Gardani, Gore, Guyatt, Guyatt, Hachimi-Idrissi, Hesketh, Higi, Kaiser, Kang, Massa, McCabe, Musso, Navari, Sanofi-Aventis Canada Inc, Schnell, Shillingburg, Shiu, Smith, Smith, Wit   +31 more
core   +1 more source